[FinancialReports](/) / [Companies](/companies/search/) / [United Kingdom](/companies/countries/united-kingdom/) / **CIZ** ![CIZZLE BIOTECHNOLOGY HOLDINGS PLC logo](https://cdn.financialreports.eu/financialreports/media/CIZZLE%20BIOTECHNOLOGY%20HOLDINGS%20PLC/other/CIZZLE_BIOTECHNOLOGY_HOLDINGS_PLC-logo.png) # CIZZLE BIOTECHNOLOGY HOLDINGS PLC — Investor Relations & Filings Ticker · **CIZ** ISIN · **GB00BNG2VN02** LEI · **213800G3OS3SA2J1Y358** IL Professional, scientific and technical activities [Open in API](/api-solutions/) Overview Filings 328 Financials Market data Peer group API Filings indexed 328 across all filing types Latest filing 2026-05-21 Report Publication Anno… Country GB United Kingdom Listing IL CIZ ## About CIZZLE BIOTECHNOLOGY HOLDINGS PLC Cizzle Biotechnology Holdings PLC is a cancer diagnostics developer focused on the early detection of lung cancer. The company is advancing a non-invasive, cost-effective blood test designed to identify lung cancer at its earliest stages, often before symptoms appear. The test utilizes a proprietary CIZ1B biomarker and an advanced immunoassay. Its primary goal is to improve patient outcomes by enabling swift, curative medical intervention. The technology aims to streamline the diagnostic pathway, reduce reliance on CT scans which can have high false-positive rates, and eliminate unnecessary invasive follow-up procedures. The company, a spin-out from the University of York, is conducting clinical trials to support global regulatory approval and adoption of its technology. ## Recent filings View all 328 → | Filing | Released | Lang | Actions | | --- | --- | --- | --- | | [**Notice of AGM**](/filings/cizzle-biotechnology-holdings-plc/report-publication-announcement/2026/46720367/) Report Publication Announcement Classification · 85% confidence The document is a short RNS notice (3,164 characters) announcing that the Company’s Notice of Annual General Meeting has been posted to shareholders and will shortly be available on the website. It does not include the full notice text or the resolutions themselves but merely states that the notice has been published. Under the “menu vs. meal” rule for under‐5,000‐character filings that announce the availability of a report, this should be classified as a Report Publication Announcement rather than the actual meeting notice (PSI). | 2026-05-21 | English | | | [**Group of companies' accounts made up to 2025-12-31**](/filings/cizzle-biotechnology-holdings-plc/annual-report/2026/46825647/) Annual Report Classification · 98% confidence The document is the comprehensive Annual Report for the year ended 31 December 2025. It contains all sections typical of a full-year report: company information, executive statements, strategic report, directors’ report, corporate governance, directors’ remuneration, independent auditor’s report, consolidated and company financial statements, and notes. This aligns with the definition of an Annual Report covering full financial performance (Code: 10-K). · FY 2025 | 2026-05-11 | English | | | [**Issue of Options, Salary Waivers, Incentive Plan**](/filings/cizzle-biotechnology-holdings-plc/boardmanagement-information/2026/42453365/) Board/Management Information Classification · 95% confidence The document is an announcement from Cizzle Biotechnology Holdings PLC dated 7 May 2026. It details the issue of new share options to directors, salary waivers, and a new management incentive plan (MIP) subject to shareholder approval at the next AGM. It includes detailed tables of options granted, exercise prices, and percentages of share capital. The document also includes notifications of transactions by persons discharging managerial responsibilities (PDMRs). The content focuses on director remuneration changes and share option grants rather than financial results, regulatory certifications, or general corporate governance. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The document is a formal announcement of changes in senior management remuneration and share option grants, which fits the category of Board/Management Information (MANG). The document length is substantial and contains detailed information, not just a brief announcement or report publication notice. Therefore, the most appropriate classification is MANG with high confidence. | 2026-05-07 | English | | | [**Conversion of Convertible Loan Notes**](/filings/cizzle-biotechnology-holdings-plc/capitalfinancing-update/2026/41725048/) Capital/Financing Update Classification · 95% confidence The document is an announcement from Cizzle Biotechnology Holdings PLC regarding the conversion of convertible loan notes into new ordinary shares and the subsequent admission of these shares to trading on the London Stock Exchange. It details the funding history, conversion terms, and the expected date of share admission. There are no financial statements, management discussion, or detailed financial results presented. The content focuses on capital structure changes and financing activities, specifically the conversion of loan notes into equity and the issuance of new shares. This fits the definition of a Capital/Financing Update (CAP). The document length is about 5,134 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the appropriate classification is CAP with high confidence. | 2026-05-06 | English | | | [**Final results for the year ended 31 December 2025**](/filings/cizzle-biotechnology-holdings-plc/report-publication-announcement/2026/39018269/) Report Publication Announcement Classification · 95% confidence The document is an announcement from Cizzle Biotechnology Holdings PLC dated 30 April 2026. It states that the company's Annual Report and Financial Statements for the year ended 31 December 2025 have been published and provides a link to the full report. The text itself does not contain the full Annual Report or detailed financial data but rather announces the availability of the report. The document length is 3224 characters, which is relatively short and consistent with an announcement rather than the full report. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA) rather than the Annual Report (10-K) itself. · FY 2025 | 2026-04-30 | English | | | [**£250,000 Funding Facility**](/filings/cizzle-biotechnology-holdings-plc/capitalfinancing-update/2026/33237812/) Capital/Financing Update Classification · 92% confidence The document is an RNS announcement by Cizzle Biotechnology Holdings PLC detailing its entry into a new £250,000 funding facility through the issue of convertible loan notes and warrants. It focuses on financing terms, drawdown schedule, and investor commitments, which aligns with updates on company fundraising and capital structure changes. Therefore, it is classified as a Capital/Financing Update (CAP). | 2026-04-02 | English | | ## Browse filings by year 20 years - [2026 8 filings](/companies/cizzle-biotechnology-holdings-plc/2026/) - [2025 19 filings](/companies/cizzle-biotechnology-holdings-plc/2025/) - [2024 20 filings](/companies/cizzle-biotechnology-holdings-plc/2024/) - [2023 24 filings](/companies/cizzle-biotechnology-holdings-plc/2023/) - [2022 45 filings](/companies/cizzle-biotechnology-holdings-plc/2022/) - [2021 37 filings](/companies/cizzle-biotechnology-holdings-plc/2021/) - [2020 3 filings](/companies/cizzle-biotechnology-holdings-plc/2020/) - [2019 59 filings](/companies/cizzle-biotechnology-holdings-plc/2019/) - [2018 21 filings](/companies/cizzle-biotechnology-holdings-plc/2018/) - [2017 8 filings](/companies/cizzle-biotechnology-holdings-plc/2017/) - [2016 16 filings](/companies/cizzle-biotechnology-holdings-plc/2016/) - [2015 19 filings](/companies/cizzle-biotechnology-holdings-plc/2015/) - [2014 25 filings](/companies/cizzle-biotechnology-holdings-plc/2014/) - [2013 18 filings](/companies/cizzle-biotechnology-holdings-plc/2013/) - [2012 1 filing](/companies/cizzle-biotechnology-holdings-plc/2012/) - [2011 1 filing](/companies/cizzle-biotechnology-holdings-plc/2011/) - [2010 1 filing](/companies/cizzle-biotechnology-holdings-plc/2010/) - [2009 1 filing](/companies/cizzle-biotechnology-holdings-plc/2009/) - [2008 1 filing](/companies/cizzle-biotechnology-holdings-plc/2008/) - [2007 1 filing](/companies/cizzle-biotechnology-holdings-plc/2007/) [["13", "AGM Information"], ["1", "Annual Report"], ["53", "Audit Report / Information"], ["47", "Board/Management Information"], ["48", "Capital/Financing Update"], ["22", "Declaration of Voting Results & Voting Rights Announcements"], ["20", "Director's Dealing"], ["6", "Earnings Release"], ["19", "Interim / Quarterly Report"], ["23", "M&A Activity"], ["24", "Major Shareholding Notification"], ["18", "Regulatory Filings"], ["9", "Remuneration Information"], ["42", "Report Publication Announcement"], ["51", "Share Issue/Capital Change"]] [["1", "English"]] Financial Reporting & Info Annual General Meeting Debt Information Equity Information Investor Communication M&A, Partnerships & Legal Management & Remuneration Other Filing type Language Start date End date Apply filters [Clear](/companies/cizzle-biotechnology-holdings-plc/) Report missing filing Download originals Download Markdown | | ID | Filing | Released | Lang | Actions | | --- | --- | --- | --- | --- | --- | | [2026](/companies/cizzle-biotechnology-holdings-plc/2026/) 8 filings | | | | | | | | 46720367 | [**Notice of AGM**](/filings/cizzle-biotechnology-holdings-plc/report-publication-announcement/2026/46720367/) Report Publication Announcement Classification · 85% confidence The document is a short RNS notice (3,164 characters) announcing that the Company’s Notice of Annual General Meeting has been posted to shareholders and will shortly be available on the website. It does not include the full notice text or the resolutions themselves but merely states that the notice has been published. Under the “menu vs. meal” rule for under‐5,000‐character filings that announce the availability of a report, this should be classified as a Report Publication Announcement rather than the actual meeting notice (PSI). | 2026-05-21 | English | | | | 46825647 | [**Group of companies' accounts made up to 2025-12-31**](/filings/cizzle-biotechnology-holdings-plc/annual-report/2026/46825647/) Annual Report Classification · 98% confidence The document is the comprehensive Annual Report for the year ended 31 December 2025. It contains all sections typical of a full-year report: company information, executive statements, strategic report, directors’ report, corporate governance, directors’ remuneration, independent auditor’s report, consolidated and company financial statements, and notes. This aligns with the definition of an Annual Report covering full financial performance (Code: 10-K). · FY 2025 | 2026-05-11 | English | | | | 42453365 | [**Issue of Options, Salary Waivers, Incentive Plan**](/filings/cizzle-biotechnology-holdings-plc/boardmanagement-information/2026/42453365/) Board/Management Information Classification · 95% confidence The document is an announcement from Cizzle Biotechnology Holdings PLC dated 7 May 2026. It details the issue of new share options to directors, salary waivers, and a new management incentive plan (MIP) subject to shareholder approval at the next AGM. It includes detailed tables of options granted, exercise prices, and percentages of share capital. The document also includes notifications of transactions by persons discharging managerial responsibilities (PDMRs). The content focuses on director remuneration changes and share option grants rather than financial results, regulatory certifications, or general corporate governance. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The document is a formal announcement of changes in senior management remuneration and share option grants, which fits the category of Board/Management Information (MANG). The document length is substantial and contains detailed information, not just a brief announcement or report publication notice. Therefore, the most appropriate classification is MANG with high confidence. | 2026-05-07 | English | | | | 41725048 | [**Conversion of Convertible Loan Notes**](/filings/cizzle-biotechnology-holdings-plc/capitalfinancing-update/2026/41725048/) Capital/Financing Update Classification · 95% confidence The document is an announcement from Cizzle Biotechnology Holdings PLC regarding the conversion of convertible loan notes into new ordinary shares and the subsequent admission of these shares to trading on the London Stock Exchange. It details the funding history, conversion terms, and the expected date of share admission. There are no financial statements, management discussion, or detailed financial results presented. The content focuses on capital structure changes and financing activities, specifically the conversion of loan notes into equity and the issuance of new shares. This fits the definition of a Capital/Financing Update (CAP). The document length is about 5,134 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the appropriate classification is CAP with high confidence. | 2026-05-06 | English | | | | 39018269 | [**Final results for the year ended 31 December 2025**](/filings/cizzle-biotechnology-holdings-plc/report-publication-announcement/2026/39018269/) Report Publication Announcement Classification · 95% confidence The document is an announcement from Cizzle Biotechnology Holdings PLC dated 30 April 2026. It states that the company's Annual Report and Financial Statements for the year ended 31 December 2025 have been published and provides a link to the full report. The text itself does not contain the full Annual Report or detailed financial data but rather announces the availability of the report. The document length is 3224 characters, which is relatively short and consistent with an announcement rather than the full report. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA) rather than the Annual Report (10-K) itself. · FY 2025 | 2026-04-30 | English | | | | 33237812 | [**£250,000 Funding Facility**](/filings/cizzle-biotechnology-holdings-plc/capitalfinancing-update/2026/33237812/) Capital/Financing Update Classification · 92% confidence The document is an RNS announcement by Cizzle Biotechnology Holdings PLC detailing its entry into a new £250,000 funding facility through the issue of convertible loan notes and warrants. It focuses on financing terms, drawdown schedule, and investor commitments, which aligns with updates on company fundraising and capital structure changes. Therefore, it is classified as a Capital/Financing Update (CAP). | 2026-04-02 | English | | | | 32825690 | [**Progress on Launch of Biomarker Test in USA**](/filings/cizzle-biotechnology-holdings-plc/regulatory-filings/2026/32825690/) Regulatory Filings Classification · 98% confidence The document is an official announcement from Cizzle Biotechnology Holdings PLC regarding progress on the commercial launch of a biomarker test and updates to royalty payment schedules. It is distributed via the London Stock Exchange's RNS (Regulatory News Service) and contains inside information as per UK MAR. While it discusses financial arrangements, it is a corporate news announcement rather than a formal financial report, audit, or proxy statement. It fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement regarding company operations and licensing agreements. | 2026-02-23 | English | | | | 14183511 | [**Patent Granted in Canada**](/filings/cizzle-biotechnology-holdings-plc/regulatory-filings/2026/14183511/) Regulatory Filings Classification · 98% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). It details a specific corporate development—the granting of a patent in Canada for the company's CIZ1B lung cancer biomarker test. As this is a general corporate announcement regarding business operations and intellectual property that does not fit into specific categories like financial reports, dividends, or management changes, it falls under the 'Regulatory Filings' (RNS) category. | 2026-02-04 | English | | | [2025](/companies/cizzle-biotechnology-holdings-plc/2025/) 7 filings | | | | | | | | 8101362 | [**£250,000 Convertible Loan Note Issue**](/filings/cizzle-biotechnology-holdings-plc/capitalfinancing-update/2025/8101362/) Capital/Financing Update Classification · 100% confidence The document is an announcement from Cizzle Biotechnology Holdings PLC regarding the issuance of convertible loan notes to raise £250,000. It details the terms of the financing, the use of proceeds, and the issuance of warrants. This falls under the category of company fundraising and financing activities. While it is distributed via RNS, the content is specifically a capital/financing update rather than a general regulatory filing or report publication announcement. | 2025-11-05 | English | | | | 8101284 | [**LOI with leading UK Clinical Diagnostic Group**](/filings/cizzle-biotechnology-holdings-plc/regulatory-filings/2025/8101284/) Regulatory Filings Classification · 100% confidence The document is an official announcement from Cizzle Biotechnology Holdings PLC regarding the signing of a Letter of Intent (LOI) for a partnership with a UK clinical diagnostic group. It is distributed via the Regulatory News Service (RNS) of the London Stock Exchange. Since it is a corporate announcement regarding business operations and partnerships that does not fit into specific categories like M&A (which usually implies a takeover or merger) or financial reporting, it is classified as a general regulatory filing. | 2025-11-05 | English | | | | 11398025 | [**Change of Registered Office**](/filings/cizzle-biotechnology-holdings-plc/regulatory-filings/2025/11398025/) Regulatory Filings Classification · 98% confidence The document is a short regulatory announcement (RNS) from Cizzle Biotechnology Holdings PLC regarding a change of its registered office address. It does not fit into specific categories like financial reports, director dealings, or M&A. As it is a general corporate update provided via the London Stock Exchange's RNS service, it falls under the 'Regulatory Filings' category. | 2025-10-27 | English | | | | 11392021 | [**Interim Results**](/filings/cizzle-biotechnology-holdings-plc/interim-quarterly-report/2025/11392021/) Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim results for the six months ended 30 June 2025' and contains detailed financial statements, management commentary, and operational highlights for a period shorter than a full fiscal year. It explicitly references 'International Accounting Standards 34, Interim Financial Reporting' and provides a breakdown of financial results, loss per share, and cash balances. This meets the criteria for an Interim/Quarterly Report (IR). · H1 2025 | 2025-09-30 | English | | | | 7936608 | [**Update on Clinical Laboratory Partnerships in USA**](/filings/cizzle-biotechnology-holdings-plc/regulatory-filings/2025/7936608/) Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's Regulatory News Service (RNS). It provides a corporate update regarding a partnership between Cizzle Biotechnology and Omni Health Diagnostics for the roll-out of a biomarker test, as well as updates on royalty payments. Since it is a general corporate announcement regarding business operations and partnerships that does not fit into specific categories like financial reports, board changes, or dividend notices, it is classified as a Regulatory Filing (RNS). | 2025-09-29 | English | | | | 11381503 | [**Financial Statements for the year ended 31 December 2024**](/filings/cizzle-biotechnology-holdings-plc/annual-report/2025/11381503/) Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report for the year ended 31 December 2024' for Cizzle Biotechnology Holdings PLC. It contains comprehensive sections typical of an annual report, including the Chair's Statement, Board of Directors, Strategic Report, Directors' Report, Corporate Governance Statement, Remuneration Report, Independent Auditor's report, and full consolidated financial statements (Statement of Comprehensive Income, Financial Position, Cash Flows, and Changes in Equity). It is clearly the full annual report, not an announcement or summary. · FY 2024 | 2025-09-01 | English | | | | 7749313 | [**Commercial Progress in USA**](/filings/cizzle-biotechnology-holdings-plc/regulatory-filings/2025/7749313/) Regulatory Filings Classification · 100% confidence The document is an official announcement distributed via the London Stock Exchange's RNS (Regulatory News Service). It details commercial progress, specifically a new licensing agreement and a revised royalty payment schedule for Cizzle Biotechnology Holdings PLC. Since it is a general regulatory announcement regarding business operations and financing updates that does not fit into more specific categories like 10-K, ER, or M&A, it is classified as a Regulatory Filing (RNS). | 2025-08-18 | English | | Page **1** of **22** 1 [2](?page=2#filings) [3](?page=3#filings) … [Next](?page=2#filings) ## Financials Income Balance Cash flow Other Annual Interim M K As reported Open in Google Sheets Loading financials… ### We couldn't load the financials ### No data available yet We have extracted financials for CIZZLE BIOTECHNOLOGY HOLDINGS PLC, but not for this combination of statement and period. Try a different combination. Swipe the table to view all periods, or rotate your phone for a wider view. | Line item | ! | | --- | --- | | | | | --- | --- | | Definition not yet available — coming soon. | | Source filings Every figure is sourced from a primary regulatory filing. Open any filing to see the original document. ## Market data ### Market data not available Last price Market cap volume Day range today 52-week range trailing ### Price history 1Y 5Y 10Y ## Peer group · Research and experimental development on natural sciences and engineering 627 peers | Company | Ticker | Country | Sector | | --- | --- | --- | --- | | [**1NKEMIA**](/companies/1nkemia/) Biotechnology company providing R&D and services for the li… | IKM | ES | Professional, scientific and te… | | [**2cureX AB**](/companies/2curex-ab/) Develops an IVD test using 3D tumoroids to predict patient … | 2CUREX | SE | Professional, scientific and te… | | [**Abattis Bioceuticals Corp.**](/companies/abattis-bioceuticals-corp/) Life sciences company aggregating and investing in cannabis… | ATTBF | CA | Professional, scientific and te… | | [**Abera Bioscience AB**](/companies/abera-bioscience-ab/) Develops mucosal vaccines using a proprietary Outer Membran… | ABERA | SE | Professional, scientific and te… | | [**ABION Inc.**](/companies/abion-inc/) Clinical-stage biopharma developing therapeutics for oncolo… | 203400 | KR | Professional, scientific and te… | | [**ABL Bio Inc.**](/companies/abl-bio-inc/) Develops bispecific antibody therapeutics for oncology and … | 298380 | KR | Professional, scientific and te… | | [**Abnova**](/companies/abnova-4133/) Global leader in high-throughput production of antibodies a… | 4133 | TW | Professional, scientific and te… | | [**Abpro Holdings, Inc.**](/companies/abpro-holdings-inc/) Clinical-stage biotech developing antibody therapeutics for… | ABP | US | Professional, scientific and te… | | [**Absci Corp**](/companies/absci-corp/) A generative AI drug creation company developing biologic m… | ABSI | US | Professional, scientific and te… | | [**Achiko AG**](/companies/achiko-ag/) A digital services platform for cross-border business compl… | ACHI | CH | Professional, scientific and te… | Page **1** of **63** 1 [2](?peer_page=2#peers) [3](?peer_page=3#peers) … [Next](?peer_page=2#peers) ### CIZZLE BIOTECHNOLOGY HOLDINGS PLC via the API Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec. [Get API access](/api-solutions/) [Read API reference](/developers/reference/) Base URLapi.financialreports.eu Auth headerx-api-key Company ID4889 TickerCIZ ISINGB00BNG2VN02 ### Endpoints most-used routes for this company | | | | | --- | --- | --- | | GET | /api/companies/4889/ | Company identity, sector, listing, identifiers | | GET | /api/filings/?company=4889 | Paginated list of all filings (filterable by type, date, language) | | GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status | | GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) | | GET | /api/isins/?company=4889 | All ISINs registered to this company | | GET | /api/filing-types/ | Reference: every filing-type code + category | Full reference: [API reference](/developers/reference/) · [OpenAPI schema](/api/schema/) ### cURL latest filings for CIZZLE BIOTECHNOLOGY HOLDINGS PLC ``` $ curl https://api.financialreports.eu/api/filings/?company=4889 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json" ``` ### Python requests ``` import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 4889}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"] ``` ### MCP server Claude · Claude Code · ChatGPT [Claude setup →](/integrations/claude/) [ChatGPT setup →](/integrations/chatgpt/) [Claude Code setup →](/integrations/claude-code/) ``` // MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CIZZLE BIOTECHNOLOGY HOLDINGS PLC (id: 4889)" ``` #### AI · Markdown Filings as Markdown Drop the latest filing into Claude or ChatGPT, or query via MCP from your client. [Open Markdown↗](/filings/cizzle-biotechnology-holdings-plc/report-publication-announcement/2026/46720367/) [Open in MCP↗](/integrations/claude/) [cURL endpoint$](/api-solutions/) #### Identity Legal nameCIZZLE BIOTECHNOLOGY HOLDINGS PLC HQLONDON, GB ListingIL ISINGB00BNG2VN02 LEI213800G3OS3SA2J1Y358 Sector[Professional, scientific and technical activities](/companies/sectors/professional-scientific-and-technical-activities/) Industry[Research and experimental development on natural sciences and engineering](/companies/sectors/professional-scientific-and-technical-activities/research-and-experimental-development-on-natural-sciences-and-engineering/) #### Coverage Filings indexed 328 Next annual report May 5–Jun 4, 2027 Confidence 57% ### Report missing filing Can't find a specific document? Let us know and we'll add it within 24 hours. What is missing or wrong? Your email We will notify you once the filing is added. Cancel Send report Sending… Report sent Thank you. We will check the data and update it shortly. × (function() { const tabs = document.querySelectorAll('.cmp-tabs-wrap .fr-tab'); const panes = document.querySelectorAll('.tab-pane'); function activate(target, pushHash) { tabs.forEach(t => { const isActive = t.dataset.tab === target; t.classList.toggle('fr-tab--active', isActive); t.setAttribute('aria-selected', isActive ? 'true' : 'false'); }); panes.forEach(p => { const isActive = p.dataset.pane === target; p.classList.toggle('tab-pane--active', isActive); p.hidden = !isActive; }); if (pushHash) { try { history.replaceState(null, '', '#' + target); } catch (e) {} } } tabs.forEach(tab => { tab.addEventListener('click', () => { activate(tab.dataset.tab, true); window.scrollTo({ top: 0, behavior: 'instant' }); }); }); const initial = (window.location.hash || '').replace('#', ''); const validTabs = ['overview', 'filings', 'financials', 'market', 'peers', 'api']; const legacyMap = { 'market-data': 'market', 'peer-group': 'peers' }; let target = legacyMap[initial] || (validTabs.indexOf(initial) >= 0 ? initial : 'overview'); if (target !== 'overview') activate(target, false); })();